Uncovering What Drives (and Derails) Adherence

The Challenge

Across several chronic therapy areas, patient non-adherence remains a critical obstacle to long-term treatment success. Traditional patient support programs (PSPs), while valuable, often fail to address the complex mix of cultural, psychological, and behavioral factors that influence whether patients stay on therapy.

A global pharmaceutical organization recognized the need to look beyond surface-level adherence metrics and gain a behaviorally grounded understanding of why patients discontinue treatment, even when therapies are clinically effective. The goal was to generate breakthrough insights to inform a multichannel adherence strategy, tailored both globally and locally.

The Solution

To meet this goal, the team used an immersive, mixed-method research approach that included:

• Synthesizing previous research and dialogues with PSP stakeholders to establish a foundation of existing knowledge to go beyond the knowns.
• Conducting an integrative approach of qualitative inquiry with immersive ethnographic research across multiple markets.
• Leveraging a multidisciplinary team of experts on human insights and behavior like anthropologist, Sociologist, semiotician, Behavior Science specialist.

As the study progressed, the approach was refined based on emerging insights. This included re-engaging physicians, bringing in country specific cultural experts, and shifting to a country-first reporting model followed by a global synthesis.

The Results

The research produced a comprehensive behavioral model that reshaped how adherence is understood and supported. Key outcomes included:

• A new patient journey framework reveals when, where, how and why adherence breaks down and empowers to act. By identifying the earliest signs of drop-off and tracking how it becomes entrenched, the study delivered precise, sustained interventions at every stage of the journey.
• Cultural insights challenged existing assumptions, showing how cultural beliefs around health, disease, recovery intersect with pharmacological beliefs shaping adherent as well as non-adherent behaviors.
• Recognition of the growing influence of social media and influencers normalizing non-adherent behaviors by creating a shared perception of truth that overrides clinical guidance.
• A deeper understanding of physician perspectives, revealing sub-conscious beliefs rooted in medical training, identity and ethics, and clinical experience make physicians complicit co-partners in driving non-adherence.
• Unpacked the non-adherence puzzle through the ‘mythical quadrant’; a space where Tx becomes unacceptable at the very point of stability for both patients as well as physicians. Mythical quadrant is a space where 2 truths exist and neither is fully embraced or entirely challenged.

The study delivered a behavioral blueprint with stage-specific interventions, aligning global strategy with local execution. It drove innovation in Patient Support Programs, tailored by disease, stage, and market. A rapid response in certain markets enabled immediate corrective action, while PSP investments were reassessed in high-duration therapy markets. Insights also informed 2025–26 brand planning and shaped an HCP engagement strategy by leveraging adherence-driven behaviors to enhance marketing and communication impact.